Novartis Pharma Files Applicaion Seeking Additional Indication for Glivec in Japan.Tokyo, Japan, Dec 26, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Novartis Pharma announced on December 26 that it has filed an application for an additional indication of Glivec (imatinib), its proprietary molecular-targeted agent, with the Ministry of Health, Labor and Welfare. The company expects approval in the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia acute lymphoblastic leukemia n. Abbr. ALL Lymphoblastic leukemia occurring mainly in older adults, characterized by rapid onset and progression of symptoms. Also called acute lymphocytic leukemia. (Ph + ALL). Initially approved in 2001, Glivec, a single transduction inhibitor, is now available in over 80 countries worldwide and is indicated for the treatments of chronic myelocytic leukemia chronic myelocytic leukemia Chronic granulocytic leukemia, chronic myelogenous leukemia, chronic myeloid leukemia Hematology An indolent leukemia, characterized by an ↑ in mature granulocytes in the peripheral circulation Treatment Imatinib mesylate induces and gastrointestinal stromal tumor gastrointestinal stromal tumor GIST Surgical pathology A nonmucosal GI tumor most common in the stomach Clinical Benign–leiomyoma or malignant–leiomyosarcoma, determined histologically by ↑ mitotic activity and bizarre cells, findings seen in . In Japan, it is estimated that 250-350 people develop Ph + ALL annually. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion